Eagle Pharmaceuticals, Inc. (EGRX) News

Eagle Pharmaceuticals, Inc. (EGRX): $42.89

-0.55 (-1.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter EGRX News Items

EGRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EGRX News Highlights

  • 500 - Internal server error
  • Over the past 22 days, the trend for EGRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about EGRX are LEVI, ANDA and CRL.

Latest EGRX News From Around the Web

Below are the latest news stories about Eagle Pharmaceuticals Inc that investors may wish to consider to help them evaluate EGRX as an investment opportunity.

Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin

WOODCLIFF LAKE, N.J., Jun 17, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that it has responded to the Complete Response Letter ("CRL") for its Abbreviated New Drug Application ("ANDA") for vasopressin received from the U.S. Food and Drug Administration ("FDA") in February 2021.

Yahoo | June 17, 2021

Eagle Pharmaceuticals: A Potential Reopening Play

LeoPatrizi/E+ via Getty Images As the United States continues its COVID-19 vaccination campaign and government restrictions ease, I am starting to look for discounted "re-opening plays" that could turn into long-term investments. Eagle Pharmaceuticals (EGRX) appears to be a great re-opening prospect as patients begin to return to oncology office...

Biologics on Seeking Alpha | June 16, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Eagle Pharmaceuticals, Inc.- EGRX

New York, New York--(Newsfile Corp. - June 11, 2021) - Levi & Korsinsky announces it has commenced an investigation of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/eagle-pharmaceuticals-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.To view an enhanc

Yahoo | June 11, 2021

Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021 Wire

Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021 Business Wire

Business Wire | June 1, 2021

Would Shareholders Who Purchased Eagle Pharmaceuticals' (NASDAQ:EGRX) Stock Three Years Be Happy With The Share price Today?

As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock...

Yahoo | May 30, 2021

Eagle Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows: Date: Wednesday, June 2, 2021 Time: 1:30 p.m. Eastern Time Webcast: https://wsw.com/webcast/jeff174/egrx/1863162 The presentations will be webcast live at the aforementioned times, and archived for 30 da

Business Wire | May 26, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Eagle Pharmaceuticals, Inc.- EGRX

New York, New York--(Newsfile Corp. - May 14, 2021) - Levi & Korsinsky announces it has commenced an investigation of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/eagle-pharmaceuticals-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.To view an enhanced version of this graphic, please visit:https://orders.newsfilecorp.com/files/7091/84190_bb5f21fa44b5eb2d_001full.jpgLevi & Korsinsky is a ...

Yahoo | May 14, 2021

Eagle Pharmaceuticals (NASDAQ:EGRX) Issues Earnings Results, Beats Expectations By $0.04 EPS

Eagle Pharmaceuticals (NASDAQ:EGRX) announced its quarterly earnings results on Monday. The specialty pharmaceutical company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.04, MarketWatch Earnings reports. Eagle Pharmaceuticals had a net margin of 2.65% and a return on equity of 8.50%. Eagle Pharmaceuticals stock traded up $0.46 during []

Dakota Financial News | May 11, 2021

Eagle Pharmaceuticals to Present at the 2021 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference

BioSpace | May 10, 2021

Here’s Why Summers Value Partners Exited its Eagle Pharmaceuticals (EGRX) Position

Summers Value Partners, an investment management firm, published its “Summers Value Fund LP” first quarter 2021 investor letter – a copy of which can be downloaded here. A net return of 17.5% was delivered by the fund for the Q1 of 2021, outperforming its e Russell 2000 benchmark that delivered a 12.9% return, but below […]

Yahoo | April 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6391 seconds.